MedTrace Logo

Device Mixing in Asthma, a General Practice Research Database Study

NCT01313585 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 815377

Last updated 2011-03-14

No results posted yet for this study

Summary

This study will compare the absolute and relative effectiveness of asthma management in patients on inhaled corticosteroid (ICS) maintenance therapy as Easi-breathe® (EB) - beclometasone dipropionate (BDP) breath-actuated inhaler (BAI) - and as-needed (prn) reliever medication (short-acting beta2-agonist \[SABA\] therapy) via either a BAI (i.e. Easi-breathe® \[EB\] salbutamol) or via a pressurised metered dose inhaler (MDI) (e.g. MDI salbutamol).

Conditions

Interventions

DRUG

Initiation of beclometasone via the Easibreathe device plus salbutamol via the Easibreathe device

DRUG

Initiation of beclometasone via the Easibreathe device plus salbutamol via and MDI device

DRUG

Increase of beclometasone via the Easibreathe device plus salbutamol via the Easibreathe device

DRUG

Increase of beclometasone via the Easibreathe device plus salbutamol via an MDI

Sponsors & Collaborators

  • Teva Branded Pharmaceutical Products R&D, Inc.

    collaborator INDUSTRY

  • Research in Real-Life Ltd

    lead NETWORK

Principal Investigators

  • David Price, Prof. MD · Company Director

  • Alison Chisholm, MSc · Research Project Director

Eligibility

Min Age
4 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1991-01-31
Primary Completion
2007-06-30
Completion
2010-03-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01313585 on ClinicalTrials.gov